NeoPharm CO. LTD (092730) — Financial Flexibility Index
NeoPharm CO. LTD (092730) has a Financial Flexibility Index of 0.33x as of September 2025. Free cash flow of ₩6.32 Billion (operating CF ₩5.88 Billion minus capex ₩446.60 Million) represents 0% of total liabilities (₩18.97 Billion). Check total reinvestment intensity of NeoPharm CO. LTD to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NeoPharm CO. LTD Financial Flexibility Index (2012–2024)
Historical Financial Flexibility Index trend for NeoPharm CO. LTD across 11 annual periods. For the full cash flow conversion analysis, see 092730 cash flow conversion.
Annual Financial Flexibility Index for NeoPharm CO. LTD (2012–2024)
Year-by-year free cash flow to debt coverage for NeoPharm CO. LTD. Explore debt repayment capacity of NeoPharm CO. LTD to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.40x | ₩21.71 Billion | ₩18.63 Billion | ₩15.56 Billion | ▼ -44.8% |
| 2023 | 2.53x | ₩44.09 Billion | ₩23.26 Billion | ₩17.43 Billion | ▲ +75.2% |
| 2022 | 1.44x | ₩18.97 Billion | ₩18.16 Billion | ₩13.14 Billion | ▼ -14.0% |
| 2021 | 1.68x | ₩22.00 Billion | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.6% |
| 2020 | 1.14x | ₩17.36 Billion | ₩17.07 Billion | ₩15.26 Billion | ▼ -22.8% |
| 2019 | 1.47x | ₩25.13 Billion | ₩19.22 Billion | ₩17.05 Billion | ▲ +10.9% |
| 2018 | 1.33x | ₩18.12 Billion | ₩16.18 Billion | ₩13.64 Billion | ▲ +5.0% |
| 2017 | 1.27x | ₩11.53 Billion | ₩10.65 Billion | ₩9.11 Billion | ▼ -4.9% |
| 2016 | 1.33x | ₩10.56 Billion | ₩9.16 Billion | ₩7.94 Billion | ▲ +50.5% |
| 2015 | 0.88x | ₩6.88 Billion | ₩6.09 Billion | ₩7.79 Billion | ▲ +406.0% |
| 2012 | 0.17x | ₩736.81 Million | ₩564.34 Million | ₩4.22 Billion | — |